The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .
Dose finding studies with imidapril--a new ACE inhibitor.
1 . We describe an approach involving a smaller , shorter study , leading onto a longer , larger study in which the antihypertensive effects of ascending doses of imidapril , a new ACE inhibitor , were investigated . Both studies were planned prospect ively , assuming a clinical ly useful fall in BP to be 8 mm Hg ( s.d . = 9 ) . The studies included patients with mild to moderate essential hypertension ( baseline sitting diastolic blood pressure ( SDBP ) 95 - 115 mm Hg ) . After a placebo run-in of 2 - 3 weeks patients received either placebo or imidapril 2.5 , 5 , 10 or 20 mg in the 2 week study ( n = 91 ) or imidapril 5 , 10 , 20 or 40 mg in the 4 week study ( n = 162 ) . 2 . The overall mean baseline SDBP was 103.4 mm Hg ( s.d . 0.62 ) in the initial study and 101.5 mm Hg ( s.d . 0.41 ) in the 4 week study . 3 . Compared with placebo , imidapril 10 , 20 and 40 mg significantly reduced SDBP . There was no significant difference between these doses , suggesting that 10 mg achieved maximal ACE inhibition in most patients . The 2.5 mg dose showed no significant effect . The 5 mg dose gave an intermediate effect . In both studies the overall incidence of adverse events was similar in the imidapril and placebo groups , and was not worrying
The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .